#United States #Biopharmaceutical #Bridgewater #Insmed Incorporated #NASDAQ INSM

Insmed Grants Inducement Awards under NASDAQ Rule 5635(c)(4)

On December 4, 2025, Insmed Incorporated, a globally recognized biopharmaceutical organization focused on creating innovative therapies, revealed an exciting initiative. The company has granted inducement awards to 92 new employees as part of its strategic effort to attract top talent and maintain compliance with NASDAQ Listing Rule 5635(c)(4). These awards serve as a material incentive that underscores the company's commitment to fostering a talented workforce in the competitive biopharmaceutical industry.

The Inducement Awards

These induction awards were made under the Insmed Incorporated 2025 Inducement Plan, specifically designed to facilitate such grants. The Compensation Committee of Insmed approved these awards as part of the company's broader recruitment strategy.

The new employees, who joined Insmed on November 28, 2025, received a total of 44,273 restricted stock units alongside options to acquire 2,490 shares of Insmed common stock at an exercise price of $207.77 per share—matching the company's closing market value on the NASDAQ Global Select Market at the time of the grant.

Vesting Schedules Explained

The awarded restricted stock units come with a detailed vesting plan, designed to benefit both the employees and the company in the long run. The stock units will vest over four years, with 25% of the shares becoming available each year on the anniversary of the grant, contingent upon the employee's continued tenure with Insmed during the applicable dates.

In addition, the stock options come with a more elongated 10-year term and a similar four-year vesting period. Here, 25% of the shares from the options will vest on the first anniversary after the grant, with 12.5% of the options vesting biannually, ensuring that employees are motivated to remain dedicated to the organization.

About Insmed: A Commitment to Patient-Centric Care

Insmed Incorporated is proud to be recognized as a leader in creating medicines that significantly improve patient lives, especially those grappling with serious health conditions. Their ongoing efforts are centered around developing a diverse portfolio of approved drugs, along with promising investigational therapies targeting pulmonary and inflammatory diseases. Notably, the company is advancing programs that utilize cutting-edge technologies ranging from gene therapy to AI-driven drug design.

Headquartered in Bridgewater, New Jersey, Insmed has established operations across the United States, Europe, and Japan, demonstrating its global footprint in biopharmaceutical innovation. This commitment to reaching diverse patient populations has propelled Insmed's status as one of the biopharmaceutical industry's top employers, highlighted by its recognition as the No. 1 Science Top Employer for five consecutive years.

For those interested in exploring more about Insmed’s initiatives and projects, further information can be found on their website or social media platforms, including LinkedIn, Instagram, YouTube, and X.

In conclusion, Insmed’s inducement awards mark a strategic move in building its workforce, fostering a culture that prioritizes employee engagement while simultaneously striving for excellence in patient care. These awards not only highlight the company’s recruitment strategies but also reflect its commitment to thriving within a competitive environment, ensuring that it attracts and retains the necessary talent to innovate in healthcare.